Funding by Helmholtz Enterprise for four HZI projects supported by Ascenion

As technology transfer partner of the Helmholtz Centre for Infection Research, Ascenion supports the teams in the further development of their innovative projects. We are delighted that the following four have received funding from Helmholtz Enterprise in 2023!

Citrapeutics aims to develop and commercialize medications that would restore immunity in a variety of diseases including cancer, infections, and chronic inflammation. The therapeutic approach is based on the identification of the worldwide first inhibitors of an enzyme which plays important roles in progression of cancer and loss of immune function.

DynamAI will develop an online platform that uses artificial intelligence (AI) to model drug efficacy and optimizes dosage for drug developers. The platform will offer automated and efficient solutions for drug development. The team will provide services to pharmaceutical companies and contract research organizations.

Leopard Biosciences aims to develop a new CRISPR-based technology (LEOPARD) as the leading technology for multiplex Point-of-Care molecular diagnostics. The first product based on the LEOPARD technology will be a nucleic-acid based multiplex lateral flow assay (LFA) for respiratory virus detection at the Point-of-Care. The test portfolio will since be expanded with additional LFA tests and tests for other platforms like digital PCR.

MyxoTech is a preclinical contract research organization offering drug discovery services for fee to biopharmaceutical companies. It provides access to an exceptionally diverse, unprecedented compound library sourced from a globally unique myxobacterial strain collection. Access to its state-of-the-art natural product discovery platform, including access to analytical tools, is made possible through the partnership with the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and aims to turn screening hits into pharmaceutical lead compounds for customers.